Variant | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AF EXOME | AF GENOME | Disease | Disease Class | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
14 | 64236875 | intron variant | G/A;T | snv |
|
0.700 | 1.000 | 2 | 2016 | 2019 | |||||||||||
|
14 | 64245143 | intron variant | A/G | snv | 4.4E-03 |
|
0.700 | 1.000 | 1 | 2012 | 2012 | ||||||||||
|
14 | 64244659 | intron variant | C/T | snv | 4.4E-02 |
|
0.700 | 1.000 | 1 | 2012 | 2012 | ||||||||||
|
14 | 64244659 | intron variant | C/T | snv | 4.4E-02 |
|
0.700 | 1.000 | 1 | 2012 | 2012 | ||||||||||
|
14 | 64235099 | missense variant | A/C | snv | 4.0E-06 |
|
Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Endocrine System Diseases | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||||||
|
14 | 64278681 | intron variant | T/A;C | snv |
|
0.700 | 1.000 | 1 | 2012 | 2012 | |||||||||||
|
14 | 64236875 | intron variant | G/A;T | snv |
|
0.700 | 1.000 | 1 | 2012 | 2012 | |||||||||||
|
14 | 64236875 | intron variant | G/A;T | snv |
|
0.700 | 1.000 | 1 | 2016 | 2016 | |||||||||||
|
14 | 64236875 | intron variant | G/A;T | snv |
|
0.700 | 1.000 | 1 | 2016 | 2016 | |||||||||||
|
14 | 64236875 | intron variant | G/A;T | snv |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | 1.000 | 1 | 2013 | 2013 | ||||||||||
|
14 | 64160241 | intron variant | C/T | snv | 1.6E-02 |
|
0.700 | 1.000 | 1 | 2019 | 2019 | ||||||||||
|
14 | 64226667 | intron variant | G/A | snv | 0.25 |
|
0.700 | 1.000 | 1 | 2019 | 2019 | ||||||||||
|
14 | 64212580 | intron variant | T/G | snv | 5.6E-02 |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||||||
|
0.641 | 0.600 | 14 | 64233098 | 3 prime UTR variant | C/T | snv | 0.31 | 0.33 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.030 | 0.667 | 3 | 2005 | 2014 | ||||||
|
0.641 | 0.600 | 14 | 64233098 | 3 prime UTR variant | C/T | snv | 0.31 | 0.33 |
|
Neoplasms; Male Urogenital Diseases | 0.030 | 1.000 | 3 | 2009 | 2015 | ||||||
|
0.641 | 0.600 | 14 | 64233098 | 3 prime UTR variant | C/T | snv | 0.31 | 0.33 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.030 | 0.667 | 3 | 2005 | 2014 | ||||||
|
0.641 | 0.600 | 14 | 64233098 | 3 prime UTR variant | C/T | snv | 0.31 | 0.33 |
|
Neoplasms; Male Urogenital Diseases | 0.030 | 1.000 | 3 | 2009 | 2015 | ||||||
|
0.641 | 0.600 | 14 | 64233098 | 3 prime UTR variant | C/T | snv | 0.31 | 0.33 |
|
Nervous System Diseases; Mental Disorders; Cardiovascular Diseases | 0.020 | 1.000 | 2 | 2009 | 2012 | ||||||
|
0.641 | 0.600 | 14 | 64233098 | 3 prime UTR variant | C/T | snv | 0.31 | 0.33 |
|
Behavior and Behavior Mechanisms | 0.020 | 1.000 | 2 | 2011 | 2018 | ||||||
|
0.641 | 0.600 | 14 | 64233098 | 3 prime UTR variant | C/T | snv | 0.31 | 0.33 |
|
Female Urogenital Diseases and Pregnancy Complications | 0.020 | 0.500 | 2 | 2008 | 2014 | ||||||
|
0.641 | 0.600 | 14 | 64233098 | 3 prime UTR variant | C/T | snv | 0.31 | 0.33 |
|
Mental Disorders | 0.020 | 1.000 | 2 | 2011 | 2018 | ||||||
|
0.641 | 0.600 | 14 | 64233098 | 3 prime UTR variant | C/T | snv | 0.31 | 0.33 |
|
Eye Diseases; Immune System Diseases; Endocrine System Diseases | 0.020 | 1.000 | 2 | 2008 | 2011 | ||||||
|
0.641 | 0.600 | 14 | 64233098 | 3 prime UTR variant | C/T | snv | 0.31 | 0.33 |
|
Behavior and Behavior Mechanisms | 0.020 | 1.000 | 2 | 2011 | 2018 | ||||||
|
0.641 | 0.600 | 14 | 64233098 | 3 prime UTR variant | C/T | snv | 0.31 | 0.33 |
|
Nutritional and Metabolic Diseases | 0.020 | 1.000 | 2 | 2009 | 2012 | ||||||
|
0.641 | 0.600 | 14 | 64233098 | 3 prime UTR variant | C/T | snv | 0.31 | 0.33 |
|
Nutritional and Metabolic Diseases | 0.010 | < 0.001 | 1 | 2010 | 2010 |